Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights

News provided by

May 06, 2019, 05:00 ET

DUBLIN, May 6, 2019 /PRNewswire/ -- The "Alzheimer's Disease: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.

The Alzheimer's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights report provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Alzheimer's disease.

Alzheimer's disease is a neurodegenerative condition characterized by progressive memory loss, cognitive dysfunction and dementia. Currently, it is the most commonly reported neurodegenerative disorder across the world, and the sixth leading cause of death in the US. It was estimated that, in 2018, nearly 5.7 million Americans (considering all age groups) were living with Alzheimer's disease. During the same year, Alzheimer's disease and other dementias were projected to be responsible for a healthcare burden amounting to USD 277 billion, in the US. Considering that only a limited range of diagnosis, treatment and disease management solutions are presently available, this segment of the healthcare industry is presently faced with a pressing need for accurate diagnostic (predictive) tests and efficient treatment options that have the capability to slow the progression of the condition.

Despite extensive research aimed at comprehending the etiopathogenesis of Alzheimer's disease, only six drugs have been approved since 1996 for treatment. The rate of failure of drugs being developed for treating Alzheimer's disease is alarming (~99.6%) and is even higher than that reported for cancer (~81%). Most of the existing therapeutic options have proven inadequate in arresting the progression of the disease and long term management of associated symptoms. Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to develop various types of disease-modifying interventions and drug/therapy candidates that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital and other strategic investors. In the coming years, the market is anticipated to grow at a significant pace as more novel solutions clear clinical evaluation and get commercialized.

Key Topics Covered:

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. An Overview of Alzheimer's Disease
3.1.1. Epidemiology
3.1.2. Symptoms of the Disease
3.1.3. Causes of Alzheimer's Disease
3.1.4. Stages of Alzheimer's Disease
3.2. Alzheimer's Disease Research: Government Initiatives and Programs
3.3. Management of Alzheimer's Disease
3.3.1. Interventional Therapies
3.3.2. Non-Interventional Therapies
3.3.2.1. Behavior Management
3.3.2.2. Healthy Living
3.3.2.3. Creating a Safe and a Supportive Environment
3.4. Future Perspectives

4. PIPELINE REVIEW: MARKETED AND CLINICAL DRUGS
4.1. Chapter Overview
4.2. Alzheimer's Disease Therapy: Marketed and Development Pipeline
4.3. Alzheimer's Disease Therapy: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Target Stage of Disease
4.3.4. Analysis by Type of Treatment
4.3.5. Analysis by Mechanism of Action
4.3.6. Analysis by Route of Administration
4.3.7. Analysis by Dosing Frequency
4.3.8. Analysis by Type of Therapy
4.3.9. Analysis by Path to Clinic
4.3.10. Grid Analysis: Distribution by Type of Therapy, Phase of Development and Path to Clinic
4.4. Alzheimer's Disease Therapy: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size and Geographical Location
4.4.3. Leading Developers
4.4.4. Grid Analysis: Distribution by Location, Size of Industry Players and Mechanism of Action of Pipeline Drugs
4.4.5. Analysis by Geography

5. ALZHEIMER'S DISEASE: UNMET NEEDS ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs Associated with Alzheimer's Disease
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights
5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights
5.2.4. Expert Opinions
5.2.4.1. Rudy Tanzi, Professor of Neurology, Harvard University
5.2.4.2. Samuel Cohen, CEO and Co-Founder, Wren Therapeutics
5.2.4.3. Brandon Brock, Chiropractic Neurologist / Staff Clinician, Cerebrum Health Centers
5.2.4.4. Ronald C Petersen, Director, Mayo Clinic Alzheimer's Disease Research Center and the Mayo Clinic Study of Aging
5.2.4.5. Neal Barnard, Founding President, The Physicians Committee for Responsible Medicine
5.2.4.6. Peter V Rabins, Proffesor, Johns Hopkins University School of Medicines
5.2.4.7. Joe Dispenza, International Lecturer / Professor, Quantum University
5.2.4.8. Freda Lewis-Hall, Chief Medical Officer, Pfizer
5.2.4.9. Dheeraj Roy, Professor, The Broad Institute of MIT and Harvard
5.2.4.10. Joseph Jebelli, Neuroscientist and Author
5.2.5. Summary of Key Unmet Needs associated with Alzheimer's Disease

6. CASE STUDY: TERMINATED DRUGS
6.1. Chapter Overview
6.2. Alzheimer's Disease Therapy: List of Terminated Drugs
6.2.1. Distribution of Drugs by Year of Discontinuation
6.2.2. Distribution by Phase of Discontinuation
6.2.3. Distribution by Mechanism of Action
6.2.4. Distribution of Terminated Drugs by Type of Indication
6.2.5. Distribution by Reason for Termination
6.2.6. Distribution by Affiliated Stakeholders
6.3. Alzheimer's Disease: List of Terminated Clinical Trials
6.3.1. Distribution of Study Start Year and Year of Termination of Clinical Trials
6.3.2. Distribution on Trial Region(s)
6.4. Concluding Remarks

7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Methodology
7.3. Alzheimer's Disease: List of Publications
7.3.1. Analysis by Type of Study
7.3.2. Analysis by Study Objective
7.3.3. Analysis by Type of Therapeutic Targets
7.3.4. Key Journals

8. PARTNERSHIP AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Alzheimer's Disease: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Focus Area
8.3.4. Regional Analysis
8.3.5. Most Active Players: Analysis by Number of Partnerships

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Molecules
9.3.5. Regional Analysis by Amount Invested
9.3.6. Most Active Players
9.3.7. Most Active Investors
9.4. Concluding Remarks

10. NON-PHARMACOLOGICAL INTERVENTIONS AND DIAGNOSTICS
10.1. Chapter Overview
10.2. Non-Pharmacological Interventions for Alzheimer's Disease
10.2.1. Cognition / Emotion-Oriented Interventions
10.2.1.1. Reminiscence Therapy
10.2.1.2. Simulated Presence Therapy
10.2.2. Sensory Stimulation-based Interventions
10.2.2.1. Virtual Reality
10.2.2.2. Music Therapy
10.2.2.3. Light Therapy
10.2.2.4. Aromatherapy
10.2.2.5. Reflexology
10.2.3. Other Psychosocial Interventions
10.2.3.1. Animal-Assisted Therapy
10.3. Alzheimer's Disease Therapy: List of Companies Offering Non-Pharmacological Interventions and Diagnostic Tests

11. ALZHEIMER'S DISEASE THERAPY: CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Cognition Therapeutics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Kenneth Moch, President and Chief Executive Officer
12.3. ICB International
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Ram Bhatt, Chief Executive Officer, Chairman and Founder

Companies Mentioned

23andMe
3M
AB Science
Abbott
AbbVie
Abcam
AC Immune
ACADIA Pharmaceuticals
Accera
Access Industries
Acelot
Avid Bioservices
Avineuro Pharmaceuticals
Axon Neuroscience
Axovant Sciences
Axsome Therapeutics
AZTherapies
Baillie Gifford
Bain Capital Life Sciences
Banner Alzheimer's Institute
Baxalta
BELLUS Health
BioArctic
Biogen
Biohaven Pharmaceuticals
Biomar Microbial Technologies
Biomedical Catalyst
Bionomics
BioPharmaceuticals Australia
Clera
Cleveland Clinic
Clinical Research Services Turku
Cogentis Therapeutics
Cognition Therapeutics
Congenia
Cypralis
DAE HWA Pharmaceutical
Daewoong Pharmaceutical
Dartmouth-Hitchcock Medical Center
Dawson James Securities
F-Prime Capital
Finovam
Forbion
Forrest Capital
Fortuna Fix
FORUM Pharmaceuticals
Fountain Healthcare Partners
FUJIFILM Holdings America
Grifols
Gurnet Point Capital
Lundbeck
Harvard Medical School
IBM Watson Health
IlDong Pharmaceutical
ImmunoBrain Checkpoint
Impel NeuroPharma
Imperial College London
Inflazome
Innovative California Biosciences International
INSIGHTEC
IntelGenx
Intellect Neurosciences
Intra-Cellular Therapies
Karuna Pharmaceuticals
Keio University
Myrexis
NasVax
New York State Psychiatric Institute
Novartis
Novartis Venture Fund
Optina Diagnostics
OrbiMed
OrbiMed Advisors
Orion Pharma
Oryzon
Otsuka Pharmaceutical
Oxford Drug Discovery Institute
P2D Bioscience
Pain Therapeutics
Panorama Research
PAREXEL International
Pfizer
Sangamo Therapeutics
Sanofi
Science Exchange
Senexis
Servier
Shire
SpringWorks Therapeutics
Stanford University
Stanley Family Foundation
Takeda Pharmaceutical
TauRx Therapeutics
Teijin Pharma
Tetra Discovery Partners
Teva Pharmaceutical
Transition Therapeutics
TRB Chemedica International
Treventis
TVM Capital Life Science
VA Office of Research and Development
Avalon AI
Vanderbilt University
Varinel
Wake Forest School of Medicine
Yale University
Ybrain
Zeltia

For more information about this report visit https://www.researchandmarkets.com/r/9xyp9a

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets